Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Antimicrobial Agents and Chemotherapy|December 17, 2008
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropismJames F Demarest, Heather Amrine-Madsen, David M Irlbeck, et al.
Antiviral Research|October 2, 2025
Small molecule direct-acting antivirals for treatment of mpoxE Randall Lanier, Richard L Mackman, Lee Ruggiero, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2008
Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelopeKathryn M Kitrinos, Heather Amrine-Madsen, David M Irlbeck, et al.
AIDS (London, England)|July 11, 2008
Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individualsDavid M Irlbeck, Heather Amrine-Madsen, Kathryn M Kitrinos, et al.
Antiviral Research|September 22, 2021
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviralJustin G Julander, James F Demarest, Ray Taylor, et al.
Journal of Virology|April 23, 2010
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cellsJennifer M Pfaff, Craig B Wilen, Jessamina E Harrison, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2025
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic PreparednessRuxandra Draghia-Akli, Nina M Hill, Bruce Altevogt, et al.
Viruses|January 22, 2022
Activity of Galidesivir in a Hamster Model of SARS-CoV-2Ray Taylor, Richard Bowen, James F Demarest, et al.
Journal of Clinical Pharmacology|August 5, 2008
In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of AplavirocJames F Demarest, Sara S Sparks, Kathleen Schell, et al.
AIDS Research and Human Retroviruses|January 9, 2010
HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entryJohn C Tilton, Heather Amrine-Madsen, John L Miamidian, et al.
Pageof 2